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ABSTRACT 
Obesity is currently one of the greatest global health problems. It is associated with 
increased morbidity and mortality, worsened quality of life (QOL) and significant 
health care costs. For morbidly obese patients, bariatric surgery is the only effective 
treatment option showing good and sustainable long-term weight loss and remission 
or improvement of obesity related comorbidities. Laparoscopic Roux-en-Y gastric 
bypass (LRYGB) is the gold standard of bariatric surgery with demonstrated long-
term efficacy. During the last years, laparoscopic sleeve gastrectomy (LSG) has 
become the most common bariatric procedure despite the lack of long-term follow-
up results at that time.  
The main aim of this thesis was to compare the short and long-term outcomes on 
weight loss, obesity related co-morbidities, and QOL after LSG and LRYGB in the 
treatment of morbid obesity in a randomized clinical multicenter equivalence trial 
(SLEEVEPASS). In addition, this thesis aimed to assess the QOL improvement after 
laparoscopic gastric banding (LGB) and to compare it with the QOL of the general 
population.  
The operative time of LSG was shorter with no difference in early (30 days) 
overall morbidity between LSG and LRYGB. At 5-year follow-up, the primary 
endpoint of percent excess weight loss (%EWL) was 57% after LRYGB and 49% 
after LSG. The mean difference was not statistically significant based on the 
prespecified equivalence margins. At 5 years, there were no differences regarding 
the long-term resolution of type 2 diabetes or dyslipidemia, improvement of QOL, 
morbidity, and mortality, but hypertension resolution was superior after LRYGB. 
QOL improved significantly after LAGB and was maintained at five-year follow-up 
but did not reach the level of the general population. 
KEYWORDS: Bariatric surgery, Morbid obesity, Laparoscopic gastric bypass, 
Laparoscopic sleeve gastrectomy, Laparoscopic gastric banding 
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TIIVISTELMÄ 
Lihavuus on yksi suurimpia maailmanlaajuisia terveysongelmia. Siihen liittyy 
lisääntynyt sairastavuus ja kuolleisuus, huonontunut elämänlaatu sekä merkittäviä 
terveydenhuollon kustannuksia. Lihavuuskirurgia on ainoa hoitomuoto, jolla 
saavutetaan hyvät pitkäaikaistulokset painonlaskun sekä sairaalloiseen lihavuuteen 
liittyvien liitännäissairauksien paranemisen osalta. Mahalaukun ohitusleikkaus 
(bypass) on vakiintunut leikkausmenetelmä, jonka teho on osoitettu pitkäaikais-
seurannassa. Viime vuosina mahalaukun kavennusleikkauksesta (sleeve) on tullut 
yleisin lihavuuskirurginen leikkausmenetelmä ilman käytettävissä olevia pitkä-
aikaistuloksia.  
Tämän väitöskirjatyön tarkoituksena oli vertailla mahalaukun kavennus- ja 
ohitusleikkauksen tuloksia painonlaskun, liitännäissairauksien paranemisen sekä 
elämänlaadun osalta satunnaistetussa kliinisessä monikeskus-ekvivalenssitutki-
muksessa (SLEEVEPASS). Lisäksi tutkittiin mahapantaleikkauksen jälkeistä 
elämänlaadun paranemista ja vertailtiin sitä väestön yleiseen elämänlaatuun. 
Varhaisvaiheen tuloksissa kavennusleikkauksen leikkausaika oli lyhyempi, 
mutta komplikaatioiden määrässä ei ollut eroa ohitusleikkaukseen verrattuna. 
Tutkimuksen ensisijainen päätetapahtuma eli ylipaino-osuuden prosentuaalinen 
lasku (%EWL) viiden vuoden seurannassa oli ohitusleikkauksen jälkeen 57% ja 
kavennusleikkauksen jälkeen 49%. Keskimääräinen ero ei ollut tilastollisesti 
merkitsevä perustuen ennalta määriteltyihin ekvivalenssirajoihin. Leikkausmene-
telmien välillä ei ollut eroa tyypin 2 diabeteksen, hyperkolesterolemian ja 
elämänlaadun paranemisessa, eikä sairastavuudessa ja kuolleisuudessa, mutta 
verenpainetauti parani useammin ohitusleikkauksen jälkeen. Mahapantaleikkauksen 
jälkeen elämänlaatu parani merkitsevästi viiden vuoden seuranta-aikana, mutta 
lihavuuskirurgisten potilaiden elämänlaatu oli vertailuväestöä huonompi. 
AVAINSANAT: Lihavuuskirurgia, Sairaalloinen lihavuus, Laparoskooppinen 
mahalaukun ohitusleikkaus, Laparoskooppinen mahalaukun kavennusleikkaus 
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1 Introduction 
Obesity, defined as an excess of body fat, is a chronic disease. During the last 
decades, the obesity epidemic has become one of the biggest global health problems 
with increasing prevalence around the world. It is considered a major contributor to 
poor health in most countries (NCD-RisC 2016). It has been estimated that in 2015 
approximately 604 million adults and 108 million children were obese representing 
a doubling in obesity prevalence in 70 countries and an increase in the prevalence in 
almost all countries since 1980 (Afshin et al. 2017). In the year 2000, it was estimated 
that the number of overweight adults surpassed the number of underweight adults 
for the first time in the world (Caballero 2007).  
Obesity is associated with increased morbidity and mortality, worsened quality 
of life (QOL) and significant health care costs. All of these associations are based 
mainly on obesity-related comorbidities, such as type 2 diabetes mellitus (T2DM), 
hypertension and other cardiovascular diseases, hyperlipidemia, obstructive sleep 
apnea (OSA) and depression. (Calle et al. 1999)  
Results with conservative treatment, such as nutritional counseling, dietary 
therapy, physical activity counseling, behavioral therapy and pharmacological 
therapy, have been disappointing, in particular in the long term. Bariatric surgery is 
considered the only effective treatment option for morbidly obese patients showing 
good and sustainable weight loss and remission or improvement of obesity related 
comorbidities. (Adams et al. 2018, Puzziferri et al. 2014, Sjöström 2013) For many 
years, laparoscopic Roux-en-Y gastric bypass (LRYGB) was the most frequently 
performed bariatric procedure in the world (Angrisani et al. 2018) and considered 
the gold standard of bariatric surgery. Its long-term efficacy regarding weight loss, 
resolution of obesity-related comorbidities and complication rates has been well 
demonstrated (Adams et al. 2018, Buchwald et al. 2004). 
As the first laparoscopic minimally invasive bariatric procedure, laparoscopic 
adjustable gastric banding (LAGB) became popular in the 1990s and early 2000s 
(Angrisani et al. 2018). However, the long-term results have been rather 
disappointing due to increasing number of complications, such as band slippage 
requiring band removal, and insufficient weight loss (Suter et al. 2006). Nowadays, 
LAGB is performed less frequently, and has been almost abandoned in Europe 
Mika Helmiö 
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(Angrisani et al. 2018), and many of the earlier LAGB patients have been converted 
to other bariatric procedures.  
Laparoscopic sleeve gastrectomy (LSG) is currently the most common bariatric 
procedure worldwide and in 2014, the number of LSGs surpassed the number of 
LRYGBs (Angrisani et al. 2018). LSG was initially developed as a first stage 
procedure in biliopancreatic diversion with duodenal switch (BPD-DS) in super 
obese patients to reduce surgery related morbidity and mortality (Hess and Hess 
1998). As weight-loss results following LSG were more promising than expected, it 
started to gain popularity as a single stage procedure in morbidly obese patients. The 
advantages of LSG over LRYGB include a technically less complex procedure with 
shorter operation time, no risk of internal herniation, the remnant stomach still 
accessible for endoscopy, less dumping due to preservation of the pylorus, and that 
various second stage procedures are possible, if required. 
In this doctoral thesis, the aim of study I was to assess the changes in QOL after 
LAGB performed for morbid obesity. In addition, the QOL of the LAGB bariatric 
surgery patients was compared to the QOL of an age and gender standardized general 
population. Studies II, III, and IV were parts of a randomized, clinical, multicenter 
equivalence study (SLEEVEPASS trial). The aim of study II was to compare 
perioperative outcomes and 30-day morbidity after LSG and LRYGB for the 
treatment of morbid obesity. In study III, the six-month results on weight loss, 
remission of obesity-related comorbidities and overall morbidity after LSG and 
LRYGB were assessed. The aim of study IV was to determine the outcomes of LSG 
and LRYGB at 5-year follow-up regarding the primary endpoint percent excess 
weight loss (%EWL) and the secondary outcomes remission of obesity-related 
comorbidities, overall morbidity, and improvement of QOL. 
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2 Review of the Literature 
2.1 Obesity 
2.1.1 Classification and epidemiology of obesity 
Obesity is defined as an excess of body fat that may cause problems to an 
individual’s health. Body mass index (BMI) calculated as weight in kilograms 
divided by the square of height in meters (kg/m2) is used for classifying the degree 
of obesity. The recommended classifications for BMI adopted by the National 
Institutes of Health (NIH) and World Health Organization (WHO) are: people with 
BMI < 18.5 kg/m² are considered underweight, 18.5 to 24.9 kg/m² normal weight, 
25.0 to 29.9 kg/m² overweight, and people with BMI ≥ 30.0 kg/m² are considered 
obese. Obesity is further categorized into three classes: class I (moderately obese) 
for BMI 30.0 to 34.9 kg/m², class II (severely obese) for BMI 35.0 to 39.9 kg/m², 
and BMI ≥ 40.0 kg/m² is class III, very severely obese or morbidly obese. (National 
Institutes of Health 1998, World Health Organization 2000)  
Obesity is a chronic disease with an increasing prevalence around the world. It 
is considered a major contributor to poor health in most countries. (NCD-RisC 2016) 
It has been estimated that approximately 604 million adults and 108 million children 
were obese in 2015 globally. This represents a doubling in the prevalence of obesity 
in 70 countries and increased prevalence in almost all other countries since 1980 
(Afshin et al. 2017). There are differences in the prevalence of obesity regarding 
different regions and countries: 4% to 28% of men and 6% to 37% of women in 
European countries are obese with Eastern and Southern Europe having higher 
prevalence rates (Berghöfer et al. 2008). According to a 2014 WHO report, 61% of 
people in the Americas were overweight and 27% were obese, whereas in South-
East Asia only 22% were overweight and 5% obese (World Health Organization 
2014). In Finland, according to the FinHealth 2017 study, the prevalence of 
overweight is 72% and obesity 26% in men, and 63% and 28% in women, 
respectively (Koponen et al. 2018). 
Mika Helmiö 
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2.1.2 Obesity related morbidity and mortality  
Obesity is associated with increased morbidity and mortality (Wang et al. 2011, 
Haslam and James 2005). Health risks related to obesity start to increase already at 
BMI > 25 kg/m² (Field et al. 2001). The worldwide incidence of especially T2DM, 
cardiovascular diseases, OSA, cancer, and osteoarthritis is strongly influenced by the 
obesity epidemic (Seidell and Halberstadt 2015). Other comorbidities associated 
with obesity are, for example, non-alcoholic fatty liver disease (NAFLD), non-
alcoholic steatohepatitis (NASH), cirrhosis, gallstones, gastroesophageal reflux 
disease (GERD), asthma, polycystic ovarian syndrome (PCOS), infertility, urinary 
incontinence, gout, and depression (Nguyen and El-Serag 2010, Martin-Rodriguez 
et al. 2015, Bächler et al. 2014). 
There is strong evidence from several large epidemiologic studies that obesity is 
associated with an increased risk of mortality (Adams et al. 2006, Freedman et al. 
2006, Pischon et al. 2008). An analysis of a UK primary care database (Clinical 
Practice Research Datalink, CPRD) between 1988 and 1998 identified the following 
factors to be associated with increased risk of death in the severely obese population 
(BMI ≥ 35 kg/m²): T2DM, age, male sex and smoking (Padwal et al. 2013). In 
addition to these factors, a recent case-controlled analysis from the same UK 
database including almost 190 000 patients identified also BMI ≥ 60 kg/m², 
hypertension, and hyperlipidemia at first diagnosis of severe obesity to be 
independently associated with an increased risk of death (Moussa et al. 2019).  
2.1.3 Economic impact of obesity 
The treatment of obesity-related conditions accounts for an enormous economic 
burden (Wang et al. 2011, Finkelstein et al. 2008). In addition to direct health care 
expenses, obesity also imposes costs in the form of lost work days, lower 
productivity at work, and permanent disability. It has been described that there is an 
association between increasing BMI and costs attributable to obesity (Dee et al. 
2014, Specchia et al. 2015). In 2014, the global economic impact of obesity was 
estimated to be 2.0 trillion US dollars or 2.8% of the global gross domestic product 
(Tremmel et al. 2017).  
The Swedish Obese Subjects (SOS) study is a large prospective matched 
controlled intervention study that started in 1987 and compares bariatric surgery with 
conservative treatment of morbid obesity (Sjöström 2013). A cross-sectional 
comparison was conducted between obese patients from the SOS study and 
randomly selected references. It was found that individuals with obesity had twice 
as many days of sick leave, were three times as likely to draw a disability pension, 
and had higher annual drug costs compared with non-obese (Narbro et al. 2002). 
Review of the Literature 
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2.2 Conservative treatment of obesity 
To be successful, conservative treatment of obesity must include multimodal life-style 
interventions and long-lasting changes in many aspects of life. Conservative treatment 
of obesity can consist of nutritional counseling, dietary therapy, physical activity 
counseling, behavioral therapy and pharmacological therapy. Unfortunately, 
conservative treatment options suffer from a high rate of failure at long-term follow-
up and in most of the cases, only slow down the process of obesity and associated 
comorbidities at the best. (Kissane and Pratt 2011, Picot et al. 2009, Terranova et al. 
2015, Franz et al. 2015) In the SOS study the mean change in body weight was -16% 
in the surgery group and -1% in the conventionally treated control group at 15-year 
follow-up (Sjöström et al. 2012). In reality, the outcome of conservative treatment in 
the SOS study may be even more disappointing as the results are only presented 
according to intention-to-treat analysis, and a considerable number of patients in the 
control group have ultimately undergone bariatric surgery later during the follow-up. 
Pharmacological therapy is seldom recommended as a first-line treatment option 
for obesity. However, it can be used as an additional weight-reducing intervention 
to other conservative treatment modalities. Medical therapy can be considered for 
patients with BMI over 30 kg/m² or for patients with BMI over 28 kg/m² with 
obesity-related comorbidities. (Current Care Guidelines 2013)  
Among the pharmacological options for obesity currently available in Finland, 
orlistat (Xenical®) has been in use for the longest time. The weight-reducing effect 
is based on inhibition of pancreatic enzymes resulting in reduced intestinal uptake of 
fat. It has a modest efficacy and the side effects are quite common resulting in 
compromised treatment compliance. The most common side effects are fatty or oily 
stools and fecal urgency. In a randomized placebo-controlled study by Richelsen et 
al, the addition of orlistat to lifestyle interventions was associated with maintenance 
of an extra 2.4 kg weight loss at three-year follow-up. (Richelsen et al. 2007) 
Since the beginning of 2018, there has been a medication combining bupropion 
and naltrexone (Mysimba®) available on the market in Finland. It affects the energy 
balance via the central nervous system by reducing appetite and increasing energy 
expenditure (Greenway et al. 2009). Treatment with Mysimba® has been reported to 
result in an average of 5% weight reduction after one year treatment, when compared 
to placebo (Hollander et al. 2013, Greenway et al. 2010, Apovian et al. 2013). 
Liraglutide (Victoza®) is a drug that has previously been used for management 
of T2DM as a subcutaneous injection. It has been made available for obesity 
treatment since June 2018 in Finland. It has an appetite suppressing effect via brain 
glucagon-like peptide-1 (GLP-1) receptors. In one study, liraglutide combined with 
diet and exercise was associated with an average of 8.4 kg weight reduction, 
compared to 2.8 kg in the placebo group, with a 56-week follow-up time (Pi-Sunyer 
et al. 2015).  
Mika Helmiö 
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2.3 Operative treatment of obesity 
2.3.1 History of bariatric surgery 
The first weight-reducing operation dates back to 1952, when a Swedish surgeon 
Viktor Henriksson reported on resecting 105 cm of the small intestine (Henriksson 
1952). Dr Richard Varco at the University of Minnesota is acknowledged as the first 
to perform jejunoileal bypass (JIB) on a morbidly obese patient in 1953, but he never 
published this case (Buchwald 2014). In 1954, Kremen, Linner, and Nelson, also 
from the University of Minnesota, were the first to report of the JIB operation 
(Kremen et al. 1954). Since the publication of a refined JIB technique by Payne and 
DeWind in 1969, it became the standard weight-reducing operation for a while. In 
this technique, 35 cm of proximal jejunum was attached to the terminal ileum 10 cm 
from the ileocecal valve. (Payne and DeWind 1969) These extremely malabsorptive 
surgical techniques were highly effective, but induced major adverse effects such as 
steatorrhea, electrolyte imbalances, vitamin and mineral deficiencies, kidney stones, 
gas bloat syndrome, steatohepatitis, and progressive liver disease caused by the 
surgically created short bowel syndrome and bacterial overgrowth in the bypassed 
small intestine. In many cases the anatomy had to be restored to normal. These 
problems led to more or less abandoning of the JIB technique in the early 1970s. 
(Brown et al. 1974, Scott et al. 1971) 
Professor Nicola Scopinaro from Genoa explored the possibility to reduce some 
of the morbidity associated with JIB without compromising the weight-reducing 
effect. To achieve this, he hypothesized that the terminal ileum must be preserved 
and the bypassed intestine must have a continuous flow of contents to prevent 
bacterial overgrowth. To address this hypothesis, he developed the biliopancreatic 
diversion (BPD) in 1976. (Scopinaro et al. 1980) Marceau and Hess further refined 
it into BPD with duodenal switch (BPD-DS) in 1998 (Hess and Hess 1998, Marceau 
et al. 1993). These techniques are described in more detail in chapter 2.3.3.4. 
In 1966, Edward E. Mason performed the first gastric bypass operation at the 
University of Iowa. He was aiming for a weight-loss procedure with less 
malabsorption than JIB and adding restriction for weight reduction. This operation 
included horizontal division of the stomach and constructing a loop 
gastrojejunostomy to the proximal gastric pouch of about 100-150 ml in size. (Mason 
and Ito 1967) This original technique was modified since and in 1977 Alder 
described a smaller 50 ml gastric pouch formed by cross-stapling the stomach and 
introducing the Roux-en-Y reconstruction. This provided more gastric restriction 
and reduced the risk of anastomotic ulcer. (Alder and Terry 1977) With the 
introduction of laparoscopic approach in 1994 (Wittgrove et al. 1994), laparoscopic 
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Roux-en-Y gastric bypass (LRYGB) became the most common bariatric procedure 
in the world for two decades (Buchwald 2014). 
Aiming for a less invasive procedure, various iterations of gastroplasty as a 
restrictive procedure have been developed since the 1970s. The original version by 
Printen and Mason in 1973 consisted of a partial horizontal transection of the 
stomach, leaving a greater curvature conduit and a small connective portion between 
the gastric parts (Printen and Mason 1973). In 1981, Laws and Piatadosi made the 
pouch vertical and introduced a silastic ring to support and restrict the opening (Laws 
and Piantadosi 1981). In 1982, Edward E. Mason described the vertical banded 
gastroplasty (VBG), with a mesh band through a gastric window to restrict the outlet 
(Mason 1982). However, the long-term results were disappointing with 
unsatisfactory weight loss and complications, such as development of gastro-gastric 
fistulas and enlargement of pouches. The technique was abandoned in the 1990s with 
the ascendancy of the laparoscopic adjustable gastric banding (LAGB) (Angrisani et 
al. 2018). 
LAGB was first introduced in 1993 (Belachew et al. 1994). As the first 
laparoscopic less invasive procedure, it gained popularity in the 1990s and early 
2000s (Angrisani et al. 2018). Similar to VBG, the mid-term results even up to five 
years were good, but the long-term results beyond ten years were disappointing due 
to insufficient weight loss and increasing number of complications such as band 
erosions and slippages (Suter et al. 2006). Nowadays, LAGB is almost an abandoned 
procedure in most of the countries in Europe and many patients have been converted 
to other bariatric procedures. Currently, the majority of the few LAGBs are 
performed in the US and Australia. (Angrisani et al. 2018) 
Laparoscopic sleeve gastrectomy (LSG) was developed as a first-stage operation 
for high-risk super-obese patients before the definitive bariatric procedure, originally 
the BPD-DS (Regan et al. 2003). The initial results with LSG were surprisingly 
promising as it was shown to be effective as a primary operation. However, long-
term results exceeding five years are currently still not available. In 2014 LSG 
became the most commonly performed bariatric operation in the world (Angrisani 
et al. 2018). 
2.3.2 Indications and contraindications for bariatric surgery 
Bariatric surgery can be considered for patients with severe or morbid obesity if 
conservative treatment has failed. In 1991, The National Institutes of Health (NIH) 
Consensus Development Panel has published recommendations for gastrointestinal 
surgery for severe obesity (National Institutes of Health conference 1991). These 
recommendations with minor variations are still followed worldwide including 
Finland (Table 1). In Finland, age limits are set between 18 and 65 years, but 
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individual evaluation is possible (Current Care Guidelines 2013). On the other hand, 
the International Diabetes Federation recommends bariatric surgery for patients with 
uncontrolled T2DM even with BMI between 30 and 35 kg/m² (Dixon et al. 2011). 
All contraindications for bariatric surgery are relative and all the pros and cons must 
be weighed individually as in all surgical treatment. 
Table 1.  Indications and contraindications for bariatric surgery 
Indications Contraindications 
BMI over 40 kg/m² or 
BMI over 35 kg/m² with obesity related disease 
- type 2 diabetes mellitus 
- hypertension 
- hyperlipidemia 
- severe osteoarthritis 
- obstructive sleep apnoea 
- obesity-induced cardiomyopathy 
- polycystic ovario syndrome 
Age between 18-60 years 
Conservative treatment has failed 
Severe eating disorder 
Severe and active psychiatric disease 
Drug or alcohol abuse 
Active ulcer disease 
Inability to understand instructions 
2.3.3 Current most common operative techniques and their 
mechanisms of effect 
2.3.3.1 Laparoscopic Roux-en-Y gastric bypass (LRYGB) 
LRYGB has been the most frequently performed bariatric procedure for many years 
until 2014, when it was surpassed by LSG. In 2016, there were nearly 686 000 
bariatric operations performed worldwide, and 30% (approximately 191 000 
procedures) of these were LRYGBs. (Angrisani et al. 2018)  
Regarding the current standard LRYGB technique, a small gastric pouch 
(approximately 30 to 50 ml) is created by dividing the upper part of the stomach 
(Figure 1). The jejunum is anastomosed to the gastric pouch at approximately 50-70 
cm distal to the ligament of Treitz. From this gastrojejunal anastomosis, the length 
of the alimentary limb is measured approximately 150 cm, and a jejunojejunal 
anastomosis is created between the alimentary and the biliopancreatic limbs. Then 
the jejunum is transected between the two anastomoses completing the Roux-en-Y 
configuration. Food is diverted from the gastric pouch directly into the jejunum, thus 
bypassing the gastric remnant, duodenum and proximal jejunum. In this standard 
technique, the length of the common channel after the jejunojejunal anastomosis 
varies depending on the total length of the small intestine, which has a large 
individual variation. Many surgeons have introduced several variations of this 
Review of the Literature 
 19 
technique regarding the lengths of the intestinal limbs, with the intention to modify 
the degree of malabsorption. A longer alimentary limb does not seem to result in 
significant effect on weight loss (Choban and Flancbaum 2002). Some 
nonrandomized observational studies have reported better weight loss with a longer 
biliopancreatic limb (MacLean et al. 2001, Leifsson and Gislason 2005, Nergaard et 
al. 2014). A randomized controlled trial (RCT) on the subject was published by 
Homan et al in 2018 (Homan et al. 2018). They compared a standard LRYGB 
(alimentary limb 150 cm, biliopancreatic limb 75 cm) with a long biliopancreatic 
limb LRYGB (alimentary limb 75 cm, biliopancreatic limb 150 cm). A significantly 
better %EWL was achieved with the long biliopancreatic limb LRYGB across the 
four-year follow-up, but no difference in percent total weight loss (%TWL) was 
observed after four years. (Homan et al. 2018) 
In LRYGB, the amount of food intake is reduced due to the small gastric pouch. 
The weight reduction is enhanced by changes in the intestinal hormone levels (e.g. 
GLP-1, peptide YY, anti-incretin factors, and ghrelin) (Yousseif et al. 2014, Korner 
et al. 2005, Rubino et al. 2010). 
 
Figure 1.  Laparoscopic Roux-en-Y gastric bypass, LRYGB. Picture modified from textbook 
Surgery (Leppäniemi et al 2018), artist Tiina Ripatti. Reproduced with the permission of 
the copyright holders. 
2.3.3.2 Laparoscopic sleeve gastrectomy (LSG) 
LSG has increased rapidly in popularity since its introduction and in 2014 it became 
the most commonly performed bariatric procedure in the world. In 2016, 54% of all 
the bariatric operations performed worldwide were LSGs, comprising a total of 
approximately 340 000 operations. (Angrisani et al. 2018)  
Gastric pouch 
Alimentary limb 
Biliopancreatic limb 
Common channel 
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LSG is a partial vertical gastrectomy in which the majority of the greater 
curvature and the whole fundus are resected creating a tubular shaped stomach. 
Approximately 1/3 of the stomach is preserved including the pylorus and most of the 
antrum (Figure 2). LSG is considered mainly a restrictive weight-reducing operation 
by nature, but it also has additional metabolic effects via changes in release of 
intestinal hormones (GLP-1, peptide YY, cholecystokinin (CCK), and ghrelin) 
(Yousseif et al. 2014, Mans et al. 2015). 
 
Figure 2.  Laparoscopic sleeve gastrectomy, LSG. Picture modified from textbook Surgery 
(Leppäniemi et al 2018), artist Tiina Ripatti. Reproduced with the permission of the 
copyright holders. 
2.3.3.3 Laparoscopic adjustable gastric banding (LAGB) 
LAGB was the second most performed bariatric procedure in the world in 2008, 
representing about 42% of all procedures. Since then, the technique has been nearly 
abandoned due to high rates of insufficient weight loss and complication leading to 
band removal. (Suter et al. 2006) In 2016, there were approximately 19 000 LAGB 
operations performed in the world representing only about 3% of all the bariatric 
operations. According to the IFSO Worldwide Survey 2016, most of the LAGB 
operations still left, were performed in USA, France, Italy and Australia. (Angrisani 
et al. 2018) 
LAGB is a purely restrictive procedure. A tight, adjustable silicone ring is placed 
around the cardia of the stomach. The silicone ring is connected via a tube to an 
infusion port placed in the subcutaneous tissue, usually in the middle part of the 
sternum. The port can be accessed with a syringe and a needle. Injection of saline 
into the port leads to reduction in the band diameter, resulting in an increased degree 
of restriction (Figure 3). 
Resected part of stomach 
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Despite being the essence of the LAGB method, adjustability has also been a 
drawback. To be successful, LAGB requires an extensive follow-up program with 
continuous fine tuning adjustments and repeated nutritional advice. This requires 
dedicated health care professionals and considerable resources from the heath care 
systems. 
 
Figure 3.  Laparoscopic adjustable gastric banding, LAGB. Picture adapted from textbook Surgery 
(Leppäniemi et al 2018), artist Tiina Ripatti. Reproduced with the permission of the 
copyright holders.  
2.3.3.4 Other techniques 
Despite being the most effective bariatric operations, BPD and BPD-DS have not 
become commonly used operative techniques (Crea et al. 2011). In recent years their 
popularity has further decreased, together representing only approximately 0.5% of 
all operations worldwide. The technical complexity of the procedures compared to 
other bariatric operations and a higher rate of complications such as malnutrition and 
steatorrhea have probably played a role.(Angrisani et al. 2018) Nevertheless, BPD 
and BPD-DS can be considered among the best options for a selected group of 
patients, such as super-obese (Skogar and Sundbom 2017) and patients with 
refractory diabetes (Roslin et al. 2015). 
In BPD the lower 2/3 of the stomach is resected. The small intestine in transected 
approximately 200 to 250 cm proximal to the ileocaecal valve, and the distal part of 
the small bowel is anastomosed to the gastric pouch. The biliopanceatic limb is 
anastomosed to the distal ileum about 50 cm proximal to the ileocaecal valve, 
creating a common channel of only 50 cm in length which causes severe 
malabsorption (Figure 4). 
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Figure 4.  Biliopancreatic diversion, BPD. Picture modified from textbook Surgery (Leppäniemi et 
al 2018), artist Tiina Ripatti. Reproduced with the permission of the copyright holders. 
BPD-DS can be carried out as a single or two-staged operation. As a first step, an 
LSG is performed. Then as a second step, the duodenum is transected immediately 
below the pylorus, and the small intestine in transected 250 cm proximal to the 
ileocaecal valve. Thereafter, the distal part of the small bowel is anastomosed to the 
proximal part of the duodenum. Finally, the biliopancreatic limb is anastomosed to 
the ileum about 100 cm prior to the ileocaecal valve, creating a common channel of 
100 cm in length (Figure 5). 
Alimentary limb 
Common channel 
Biliopancreatic limb 
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Figure 5.  Biliopancreatic diversion with duodenal switch, BPD-DS. Picture modified from textbook 
Surgery (Leppäniemi et al 2018), artist Tiina Ripatti. Reproduced with the permission of 
the copyright holders. 
The one anastomosis gastric bypass (OAGB) is also known as single anastomosis 
gastric bypass (SAGB) or mini gastric bypass (MGB). It is a modification of the 
LRYGB first published in 2001 with a markedly longer BPD-limb (Rutledge 2001). 
In 2016, this operation constituted 5% of all the bariatric operations worldwide (> 
30 000 patients) and it has been growing in popularity (Angrisani et al. 2018) despite 
lacking sufficient results from long-term follow-up. In this technique, the gastric 
pouch is created longer than in LRYGB and a small bowel loop 200 cm distal to the 
ligament of Treitz (the biliopancreatic limb) is anastomosed to the gastric pouch with 
no enteroenteral anastomosis (Figure 6). Standard LRYGB was compared with 
OAGB in a French RCT (YOMEGA trial) (Robert et al. 2019). At two-year follow-
up, the results were similar regarding %EWL and metabolic improvements. 
However, higher incidences of diarrhea, steatorrhea, and nutritional adverse events 
were observed with OAGB, suggesting a malabsorptive effect related to the 200 cm 
biliopancreatic limb of the procedure (Robert et al. 2019). 
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Figure 6.  One anastomosis gastric bypass, OAGB. Picture modified from textbook Surgery 
(Leppäniemi et al 2018), artist Tiina Ripatti. Reproduced with the permission of the 
copyright holders. 
In single-anastomosis duodenoileal bypass (SADI), a LSG is created first, and the 
duodenum is divided immediately distal of the pylorus. A small bowel loop 200-300 
cm proximal to the ileocaecal valve is anastomosed to the duodenum leaving the 
pylorus intact and no enteroenteral anastomosis (Figure 7). This technique has shown 
promising results of EWL > 100% at two to three years’ follow-up (Sánchez-
Pernaute et al. 2010) and has also been used as a second stage operation after failed 
LSG (Zaveri et al. 2019, Cylke et al. 2018). 
Biliopancreatic limb 
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Figure 7.  Single-anastomosis duodenoileal bypass, SADI. Picture modified from textbook Surgery 
(Leppäniemi et al 2018), artist Tiina Ripatti. Reproduced with the permission of the 
copyright holders. 
Laparoscopic greater curvature plication (Fried et al. 2012) and vertically placed 
removable gastric clip (Jacobs et al. 2017) are two examples of minimally invasive 
laparoscopic procedures, but so far they have not gained vast popularity and the long-
term follow-up results are either disappointing or lacking altogether. 
2.3.4 Endoscopic procedures 
Several endoscopic bariatric procedures have also been developed. The concept of 
intra-gastric balloon (IGB) is to endoscopically introduce a saline-containing 
silicone balloon into the stomach to induce restriction and a feeling of satiety 
(Mathus-Vliegen and Tytgat 2005). A novel variation of IGB includes a swallowable 
balloon that does not even require endoscopy at insertion or removal (Jamal et al. 
2019). Most often IGB has been advocated for use as a bridge to surgery, i.e. 
preceding a more definitive bariatric operation (Zerrweck et al. 2012). The potential 
to reduce complications with such a regimen remains, however, to be demonstrated 
(Coffin et al. 2017).  
An example of endoscopic gastrointestinal bypass device (EGIBD) is the 
EndoBarrier®. It is a 60 cm long plastic sheath which extends from the proximal 
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duodenum to the jejunum, thus mimicking a duodenojejunal bypass. It is a relatively 
safe procedure but has an up to 20% rate of early removal due to patient intolerance. 
The ValenTx® is a 120 cm barrier device that extends from the gastroesophageal 
junction to the jejunum also with a high rate of early removal. The %EWL results 
for these devices have been 12-40% at three-month follow-up with patients with 
T2DM not requiring antidiabetic medication while the device was in place. 
(Majumder and Birk 2013) 
New endoscopic suturing devices, such as Apollo OverStitch®, USGI-POSE®, 
and EndoCinch®, offer the potential to perform sleeve-like restrictive procedures 
transorally (Majumder and Birk 2013). The durability of this endoscopic gastric 
plication technique has not been examined (Familiari et al. 2011). 
2.3.5 Effects of bariatric surgery 
Traditionally, the primary end point of bariatric surgery has been its impact on 
weight loss. In recent years, other outcomes such as resolution of obesity-related 
comorbidities and ultimately the patients’ improved QOL after surgery have become 
more recognized. The term metabolic surgery has been taken into use, and it 
describes the many effects of surgical treatment in addition to just plain weight loss. 
Regarding these various outcomes, the superiority of bariatric surgery compared to 
conservative treatment of obesity has been documented in several studies (Adams et 
al. 2018, Puzziferri et al. 2014, Sjöström 2013).  
2.3.5.1 Effect on weight loss 
In the surgical literature, weight loss has traditionally been reported as %EWL. It is 
calculated as (initial weight − follow-up weight)/(initial weight − ideal weight 
corresponding to BMI 25) × 100%. %EWL reaching ≥ 50% postoperatively is 
usually considered a good result. Other methods used in the literature for reporting 
weight loss results include change in BMI (∆BMI), percent excess BMI loss 
(%EBMIL), and total absolute weight loss (TWL). The disadvantage of using 
%EWL is that it doesn’t reflect successful weight loss in very high BMI patients. 
This group of patients may end up with lower %EWL results despite achieving better 
absolute weight loss than lower BMI patients. Thus outcome reporting standards 
have been adopted and %TWL, calculated as (initial weight − follow-up 
weight)/(initial weight) × 100%, is now considered a better outcome measure 
compared to %EWL and %EBMIL. (Brethauer et al. 2015) 
In 2004, Buchwald et al. published a large systematic review and meta-analysis 
on different bariatric procedures. Overall %EWL for the patients was 61.2%. For 
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LRYGB, LGB, and BPD or BPD-DS the results were 61.6%, 47.5%, and 70.1%, 
respectively. (Buchwald et al. 2004)  
In a recent meta-analysis of 15 randomized controlled trials (RCTs), long-term 
outcomes of LSG versus LRYGB were compared (Yang et al. 2019). Five-year 
follow-up was reached in only five trials (Peterli et al. 2018, Schauer et al. 2017b, 
Ignat et al. 2017, Zhang et al. 2014, Yang et al. 2019). %EWL at five years was 
59.1% after LSG and 69.3% after LRYGB (Yang et al. 2019). In a current 
nonrandomized cohort study from early 2019, long-term ten-year %EWL results 
were 56.0% following LRYGB and 53.2% following LSG (Jiménez et al. 2019). 
BPD and BPD-DS are considered the most effective bariatric procedures 
regarding weight loss. In a study published in 2016, BPD resulted in excellent 
%EWL of 83% at three-year follow-up (Biertho et al. 2016). 
2.3.5.2 Effect on obesity related comorbidities 
In the often cited meta-analysis by Buchwald et al, bariatric surgery in general had 
an impressively good effect on all obesity related comorbidities (Buchwald et al. 
2004). Surgical treatment of obesity is found to be superior to conservative treatment 
in reaching glycemic control in patients with T2DM and is associated with a lower 
risk of macrovascular complications (Brethauer et al. 2013, Chen et al. 2016, 
Schauer et al. 2017b, Mingrone et al. 2015, Jiménez et al. 2012). The durability of 
glycemic control after bariatric surgery has also been under investigation. In the 
Longitudinal Assessment of Bariatric Surgery (LABS) study, among patients with 
T2DM at baseline, the remission rate at seven years postoperatively was 60.2% after 
LRYGB and 20.3% after LAGB (Courcoulas et al. 2018). In a cohort study by Fisher 
et al., 5301 obese patients (BMI ≥ 35) with T2DM were matched to 14 934 control 
patients and followed for macrovascular disease outcomes. Bariatric surgery resulted 
in lower composite incidence of cerebrovascular and coronary artery events at five 
years. (Fisher et al. 2018) Preoperative duration of T2DM and level of glycated 
hemoglobin (HbA1C) have been associated as predictors of glycemic control after 
LSG and LRYGB (Huang et al. 2018). Besides T2DM, bariatric surgery also reduces 
the burden of many other obesity-associated comorbidities including hypertension 
(Schiavon et al. 2018, Buchwald et al. 2004), hyperlipidemia (Buchwald et al. 2004, 
Mingrone et al. 2015) , stroke and coronary artery disease (Sjöström et al. 2012), 
heart failure (Aggarwal et al. 2016), OSA (Ashrafian et al. 2015, Buchwald et al. 
2004, Greenburg et al. 2009), asthma (Ulrik 2016, van Huisstede et al. 2015), NASH 
(Lassailly et al. 2015), PCOS and infertility (Skubleny et al. 2016, Milone et al. 
2016), urinary incontinence (Subak et al. 2015), and cancer incidence (Sjöström et 
al. 2009, Schauer et al. 2017a). 
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2.3.5.3 Effect on obesity related mortality 
Bariatric surgery is associated with reduced risk of overall mortality in the obese 
population (Adams et al. 2007, Telem et al. 2015, Pontiroli and Morabito 2011, 
Reges et al. 2018). A recent population study from the UK (Moussa et al. 2019) 
showed that bariatric surgery was associated with significantly reduced risk of all-
cause mortality among obese patients with BMI ≥ 35 kg/m² with a hazard ratio (HR) 
of 0.49 compared to obese controls. This was a case-controlled primary care database 
analysis including almost 190 000 patients with a median follow-up time of 98 
months. (Moussa et al. 2019) In the matched-controlled SOS interventional study, 
the cumulative overall mortality during a 16-year follow-up was 5.0% in the surgery 
group and 6.3% in the control group. The unadjusted overall HR for mortality was 
0.76 in the surgery group compared to controls and HR adjusted for age, sex, and 
risk factors was 0.71. (Sjöström et al. 2007) Data from the SOS study has also 
demonstrated that surgical treatment of obesity results in reduced number of 
cardiovascular deaths (Sjöström et al. 2012). Adams et al. conducted a large registry 
data study with a mean follow-up of 12.5 years that showed a 46% lower total cancer 
mortality rate in the surgery group compared to obese controls, with a HR of 0.54 
(Adams et al. 2009). Long-term mortality rates of bariatric patients have been shown 
to improve significantly regardless of the type of bariatric procedure performed 
(Telem et al. 2015). 
2.3.5.4 Effect on quality of life (QOL) 
Obesity has negative consequences on the physical, psychological, and social aspects 
of QOL, especially among the severely obese. Physical health is impaired due to 
comorbidities and decreased physical activity. Obesity is also associated with 
depression, low self-esteem, and eating disorders. Social relations are affected by 
weight-related stigmatization and shame. (Kushner and Foster 2000, Kolotkin et al. 
2001) Many studies have demonstrated that surgery for obesity results in significant 
and lasting improvements in patient-reported QOL outcomes (Mazer et al. 2017, 
Hachem and Brennan 2016, Strain et al. 2014, Driscoll et al. 2016, Sarwer et al. 
2010). In a systematic review and meta-analysis, bariatric surgery was reported to 
have a significant positive influence on QOL in general, but with greater influence 
on physical compared to mental aspects of QOL (Lindekilde et al. 2015).  
2.3.5.5 Economic impact of bariatric surgery 
Bariatric surgery is considered a cost-effective intervention for obese patients 
compared with non-surgical interventions (Picot et al. 2009). In the short term, 
bariatric surgery is more costly than conservative treatment of obesity, but all costs 
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can be estimated to have been recouped within two years for laparoscopic bariatric 
surgery patients (Cremieux et al. 2008). In one study, the overall cost of medication 
was significantly reduced already at one year after surgery, especially for patients 
with T2DM and OSA (Gesquiere et al. 2014). According to a Finnish cost-utility 
analysis, non-operative treatment of obesity would cost more to the healthcare 
system in Finland than surgical treatment after five years following surgery (Mäklin 
et al. 2011). Bariatric surgery in the Finnish health care system was thoroughly 
evaluated by the Finnish Office for Health Technology Assessment (FINOHTA) and 
a report was published in 2009. The results showed that surgical treatment of patients 
who suffer from morbid obesity gives significant health benefits and reduces costs 
for the healthcare system. (Ikonen et al. 2009) 
2.3.6 Mortality and complications after bariatric surgery 
In a meta-analysis published in 2017, based on 38 RCTs and involving 4030 patients, 
short‐term (≤ 30 days) all‐cause mortality after bariatric surgery was 0.18% (Cardoso 
et al. 2017). In this analysis, the specific mortality rates for LRYGB and LSG were 
0.18% and 0.24%, respectively. Open surgeries in general were associated with a 
higher mortality rate (0.31%) than laparoscopic surgeries (0.16%). (Cardoso et al. 
2017) Three large non-randomized studies on LSG show the 30-day mortality rates 
vary from 0.03% to 0.24% (Stroh et al. 2016, Sakran et al. 2016, Young et al. 2015). 
An analysis based on the Scandinavian Obesity Surgery Registry database included 
26 173 patients undergoing primary LRYGB operation for morbid obesity, and 
showed a 90-day mortality rate of 0.04% (Stenberg et al. 2014). For BPD and BPD-
DS the 30-day mortality has been reported to be 1.1% (Buchwald et al. 2007). 
A meta-analysis from 2016 found that LSG had fewer early (<30-day) major 
complications in RCTs than LRYGB (3.4% vs. 7.5%), but no statistically significant 
differences were observed for minor complications, readmission and reoperation 
rates, or mortality (Osland et al. 2016). In the SM-BOSS trial, the rate of severe 
complications (< 30-day) requiring a reoperation was 4.5% after LRYGB and 0.9% 
after LSG, but the difference was not statistically significant (Peterli et al. 2013).The 
most typical early (<30-day) complications after LRYGB are bleeding (2.0-2.1%), 
gastrointestinal leakage or abscess (1.2-1.8%), small bowel obstruction (1.0.-1.1%), 
anastomotic stricture (0.2-0.3%), and anastomotic ulcer (0.5%) (Stenberg et al. 2014, 
Alizadeh et al. 2018). After LSG, the typical early postoperative complications 
include bleeding (0.3-1.0%) and gastrointestinal leakage (0.5-1.2%) (Alizadeh et al. 
2018, Dhar et al. 2018, Berger et al. 2016).  
Gallstone disease is the most common late complication of bariatric surgery. The 
incidence of gallstone formation and cholecystectomy ten years after bariatric 
surgery have been 16–43% and 9-40%, respectively (Melmer et al. 2015). Various 
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factors may play a role in the development of gallstones following bariatric surgery: 
rapid weight loss increases the saturation of cholesterol in the bile, changes the 
mucin concentration in the gallbladder, and the emptying of the gallbladder may be 
compromised due to anatomical changes following bariatric surgery (Shiffman et al. 
1991, Shiffman et al. 1992, Everhart 1993, Bastouly et al. 2009, Iglézias Brandão de 
Oliveira et al. 2003). 
Regarding the late (>30-day) complications after LRYGB, the most important 
ones include internal herniation of the small bowel (1-16%) (Geubbels et al. 2015, 
Higa et al. 2011), ulcer at the gastrojejunal anastomosis (0.6-7.6%) (Coblijn et al. 
2014, Coblijn et al. 2015), stricture at the gastrojejunal anastomosis (0-15.9%) 
(Awad et al. 2015, Peifer et al. 2007, Gould et al. 2006), early and late dumping 
syndrome (5-20%) (Emous et al. 2018, Nielsen et al. 2016), and nutritional 
deficiencies (3.6-34.6% for various parameters) (Clements et al. 2006). Among the 
late complications after LSG, the rates of exacerbation of prevalent GERD and new 
onset (“de novo”) reflux have been reported to be 19% and 23%, respectively (Yeung 
et al. 2019). Other typical late complications after LSG are stenosis of the operated 
stomach (0.7–4%) (Cottam et al. 2006, Lalor et al. 2008), and nutritional deficiencies 
(iron 28.6%, folate 12.5%, vitamin B12 15.4%, vitamin D 86% at 4-year follow-up, 
with poor supplementation maintenance) (Ben-Porat et al. 2017). Early dumping is 
less common after SG compared to LRYGB, but no differences for late dumping 
have been reported (Emous et al. 2018).  
2.3.7 Revisional surgery after insufficient weight loss 
There are no standardized criteria for insufficient weight loss after bariatric surgery. 
Brethauer et al. suggested “a standardized outcome reporting” after bariatric surgery 
including weight loss outcomes, but criteria for insufficient weight loss were not 
included (Brethauer et al. 2015). A systematic review looking at the definition of 
failure of primary bariatric surgery concluded that in the majority of the studies 
reviewed failure was not defined, but %EWL below 50% at 18 months was the most 
frequent definition used for insufficient weight loss (Mann et al. 2015). The majority 
of patients will regain some of their weight over time. Weight regain quantified as 
percentage of maximum weight lost has had the best association with most clinical 
outcomes (King et al. 2018). Revisional surgery is needed in some of the patients 
with insufficient weight loss or weight regain (Sjöström et al. 2007, Mehaffey et al. 
2016). However, standardized outcome criteria for revisional surgery have not yet 
been established. 
In recent years, many conversions from LAGB to other bariatric procedures have 
been performed. Several studies have addressed the question whether safe revisional 
surgery should be performed as a one-step or a two-step operation for the band 
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removal and the redo procedure. In a recent systematic review and meta-analysis 
(Dang et al. 2016), no differences in the rates of complications, morbidity, and 
mortality between one-step and two-step revisions for both LRYGB and LSG were 
found. Regarding insufficient weight loss after LAGB, > 50% EWL was achieved 
after conversion to both LRYGB and LSG with no significant difference between 
the groups at five-year follow-up (Angrisani et al. 2017). 
Conversion of LSG to LRYGB is usually successful when performed for GERD 
(Crawford et al. 2017, Parmar et al. 2017). However, there is no evidence that 
standard LRYGB results in further weight reduction, if weight loss after LSG has 
been insufficient (Parmar et al. 2017). BPD-DS and its later simplified modification 
SADI have been suggested as the revisional procedures of choice for insufficient 
weight loss after LSG (Lee et al. 2019). 
Tran et al. investigated the options for revisional surgery after failed LRYGB in 
a systematic review of techniques and outcomes (Tran et al. 2016). BPD-DS, distal 
LRYGB, and banding of the gastric pouch resulted in sustained weight loss up to 
three-year follow-up with acceptable complication rates. On the other hand, revision 
of the gastric pouch and anastomosis, or revision to endoluminal procedures were 
not successful. (Tran et al. 2016) 
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3 Aims 
1) To assess the changes in disease-specific quality of life (DSQOL) and health-
related quality of life (HRQOL) after LAGB for morbid obesity, and to 
compare the HRQOL with age and gender standardized general population.  
2) To investigate the early (30-day) results regarding operating time and 
morbidity comparing LSG and LRYGB for morbid obesity.  
3) To compare the short-term results of weight loss, resolution of comorbidities 
and morbidity at six months after LSG and LRYGB for morbid obesity.  
4) To determine whether LSG and LRYGB are equivalent for weight loss at five 
years in patients with morbid obesity, and to compare the two operating 
techniques for resolution of comorbidities, morbidity, mortality and 
improvement of QOL.  
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4 Materials and Methods 
4.1 Patients 
4.1.1 Study I 
From March 2000 to October 2003, 101 consecutive patients operated by LAGB for 
morbid obesity in Vaasa Central Hospital were included in this study. The operative 
treatment was set according to standard recommendations for indications and 
contraindications. The Moorehead-Ardelt QOL questionnaire (Oria and Moorehead 
1998) was offered preoperatively to all patients. In addition to this, the 15D QOL 
questionnaire (Sintonen 2001) was offered preoperatively to the last 79 patients 
starting approximately one year since the beginning of the study. The QOL was 
assessed preoperatively and at one and five years postoperatively. In addition to this, 
the 15D QOL data from the LAGB patients was compared to 15D data from age- 
and gender- standardized general population. 
4.1.2 Studies II-IV (SLEEVEPASS trial) 
The SLEEVEPASS trial was carried out at three tertiary referral hospitals (Turku 
University Hospital, Vaasa Central Hospital, and Helsinki University Hospital). 
From April 2008 to June 2010, a total of 240 patients enrolled for surgical treatment 
for morbid obesity were randomized to undergo either LSG or LRYGB. 
Inclusion criteria for the study were age 18 to 60 years, BMI greater than 40 
kg/m2 or greater than 35 kg/m2 with a significant obesity-associated comorbidity, and 
previous adequate but failed conservative treatment. Exclusion criteria were BMI 
greater than 60 kg/m2, significant psychiatric disorder or severe eating disorder, 
active alcohol or substance abuse, active gastric ulcer disease, severe GERD with a 
large hiatal hernia, and previous bariatric surgery. 
In the SLEEVEPASS trial, all the participating patients went through a thorough 
preoperative multidisciplinary evaluation according to standard treatment protocol. 
This was carried out by an endocrinologist, dietician, and surgeon. In addition, a 
psychiatric evaluation was obtained if considered necessary. The patients were 
checked for laboratory tests and underwent upper gastrointestinal endoscopy and 
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abdominal ultrasound examination. Any revealed Helicobacter pylori infection 
and/or gastric ulcer were treated before surgery. Only symptomatic gallstones were 
considered an indication for laparoscopic cholecystectomy. 
Postoperative outcomes were assessed at 30 days, six months, one, two, three, 
and five years. Follow-up of the SLEEVEPASS study was planned to continue up to 
20 years (7, 10, 15, and 20 years). For every follow-up visit, the patients were 
evaluated at the outpatient clinic where all prespecified data were thoroughly 
recorded. Patients lost to follow-up were contacted repeatedly by telephone or mail. 
4.2 Methods 
4.2.1 Laparoscopic adjustable gastric banding (LAGB) 
A small window was created along the avascular layer behind the gastroesophageal 
junction by blunt dissection using an atraumatic endodissector (Goldfinger®, 
Ethicon Endo-Surgery). The band (Swedish Adjustable Gastric Band, SAGB, 
Obtech) was introduced to the retrogastric channel by a loop suture attached to the 
endodissector and drawn to the correct position. The band was then closed and 
secured with one suture. A small proximal pouch (approximately 2-4 ml) was created 
above the band and secured anteriorily by nonabsorbable gastro-gastric sutures. The 
catheter end of the band was then brought out through one of the trocars, connected 
to the filling port, and the port was fixed subcutaneously with sutures to the 
periosteum of the sternum. The band was left empty at the operation and later 
injected with fluid at the postoperative follow-up visits. 
4.2.2 Laparoscopic sleeve gastrectomy (LSG) 
Depending on the surgeon’s preference, the procedure was carried out either by first 
dividing the stomach or by first mobilizing the greater curvature upward until the 
angle of His by dissection of the short gastric vessels using the Harmonic Scalpel® 
(Ethicon Endo-Surgery). The stomach was resected vertically by starting with two 
sequential 4.8/60-mm green load stapler (Covidien) firings for the antrum. The 
majority of the antrum was preserved as the resection was initiated 4–6 cm proximal 
to the pylorus. The rest of the resection was carried out by approximately four 
sequential 3.5/60-mm blue-load firings. All the staple lines were reinforced 
(Covidien). The sleeve was created narrow along a 33–35-Fr calibration bougie. The 
resected stomach was removed through one of the trocar sites by a plastic retrieval 
bag (EndoCatch®, Covidien). A perioperative methylene blue test was routinely 
performed after LSG at two of the three hospitals taking part in this study. 
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4.2.3 Laparoscopic Roux-en-Y gastric bypass (LRYGB) 
The procedure was started by creating a small gastric pouch. The lesser curvature 
was dissected using a Harmonic Scalpel® and the stomach was divided horizontally 
and vertically with typically two to three linear stapler firings using reinforced 3.5/45 
and 3.5/60-mm cartridges with blue loads (Covidien) creating a small pouch. Then 
the biliopancreatic limb was measured at 50–80 cm distal to the ligamentum of 
Treitz. An antecolic end-to-side gastrojejunostomy was constructed. Depending on 
the surgeon’s preference, either a 25-mm circular stapler (OrVil®, Covidien) or a 
3.5/45-mm blue-load linear stapler (Covidien) was used for this. The omentum was 
not routinely divided. The jejunal opening in the circular stapler anastomosis was 
closed with a reinforced 3.5/45-mm blue-load linear stapler firing. The opening in 
the linear stapler anastomosis was closed with a continuous suture either manually 
or using EndoStitch® (Covidien). The alimentary limb was measured at 150 cm and 
a side-to-side jejunojejunostomy was created by a linear stapler using a 2.5/60-mm 
cartridge with white load. Depending on the surgeon’s preference, the opening in the 
anastomosis was closed either by a totally stapled technique using two reinforced 
3.5/60-mm linear stapler firings with blue loads or with a continuous suture. The 
gastrojejunostomy was checked for leaks with methylene blue. The mesenteric 
defects were not routinely closed. 
4.2.4 The Moorehead-Ardelt questionnaire 
The Moorehead–Ardelt QOL questionnaire (Oria and Moorehead 1998) is a one-
page DSQOL instrument. It includes the following five dimensions: self-esteem, 
social, sexual, and physical activity, and work capacity. Each dimension is divided 
into five levels. The total score ranges from -3 to +3 with higher score indicating 
better QOL. It is relatively simple and patient-friendly and it is commonly used in 
the evaluation of QOL following bariatric surgery.  
4.2.5 The 15D questionnaire 
The 15D QOL questionnaire (Sintonen 2001) is a generic and standardized HRQOL 
instrument. It can be used both as a profile and single index score measure. It 
includes the following 15 dimensions: breathing, mental function, speech 
(communication), vision, mobility, usual activities, vitality, hearing, eating, 
elimination, sleeping, distress, discomfort and symptoms, sexual activity, and 
depression. Each dimension is divided into five levels. The reliability, validity, 
sensitivity, discriminatory power, and responsiveness to change have been tested in 
the Finnish population (Sintonen 2001, Sintonen 1997). A representative sample of 
Finnish population with the 15D QOL data can be obtained from the National Health 
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2000 Health Examination Survey (Aromaa and Koskinen 2004). This population 
was weighted to reflect the age and gender distribution of the patients in study I to 
enable comparison of HRQOL to general population. 
4.2.6 Randomization in SLEEVEPASS trial 
The patients in SLEEVEPASS trial were randomized by a closed-envelope method 
to undergo either LSG or LRYGB with a 1:1 equal allocation ratio. The 
randomization envelopes were sealed, opaque and sequentially numbered. The 
shuffled envelopes were sent to each participating hospital. After a clinical decision 
of proceeding to operative treatment for morbid obesity, the randomization was 
carried out at the preoperative outpatient clinic visit by opening a sealed envelope 
containing the information of the assigned randomization group. The treating 
surgeons in the participating hospitals were responsible for the randomizations and 
were all part of the study team, i.e. the assessors were not blinded for group 
allocation. 
4.2.7 Outcome measures in SLEEVEPASS trial 
Weight loss defined as %EWL was determined as the primary end point. Baseline 
weight was recorded at the start of the evaluation process for bariatric surgery. The 
primary end point was originally planned to be assessed at one year follow-up, but 
was later postponed at five years, as the importance of long-term outcomes after 
bariatric surgery was better understood. This didn’t affect the sample size 
calculation. 
The secondary endpoints were predefined as remission of comorbidities, 
improvement of DSQOL, overall morbidity and mortality. At the postoperative 
follow-up visits, the recorded comorbidities (T2DM, hypertension and dyslipidemia) 
were defined as resolved (no medication), improved (reduction in medications), or 
persisting (same medication as preoperatively). At five-year follow-up, the 
remission of T2DM was also analyzed according to the American Diabetes 
Association (ADA) criteria (Buse et al. 2009) (complete remission defined as 
glycated hemoglobin (HbA1C) < 6.0% and fasting glucose < 5.6 mmol/l; partial 
remission defined as HbA1C < 6.5% and fasting glucose 5.6-6.9 mmol/l, both for at 
least one year’s duration in the absence of active pharmacologic therapy). Regarding 
dyslipidemia, the patients were evaluated for lipid disturbances (total cholesterol, 
high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides 
(TG)) at all time points. The decision to discontinue medication for dyslipidemia was 
based on the treating physician’s decision using European Society of 
Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines (Catapano et 
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al. 2011). True remission of dyslipidemia according to these guidelines (LDL < 3.0 
mmol/l and no dyslipidemia medications) was assessed at five-year follow-up for the 
patients with baseline dyslipidemia.  
Postoperative complications were classified as major or minor. A modified 
version of a classification for endoscopic biliary sphincterotomy complications was 
used (Cotton et al. 1991). Morbidity resulting in reoperation, hospital stay exceeding 
seven days, need for blood transfusions of four or more units, or death constituted a 
major complication. All other adverse events in the postoperative period were 
classified as minor complications. In addition, all late complications recorded 
between the follow-up points of 30 days and five years after surgery were 
retrospectively classified according to the Clavien-Dindo classification (Dindo et al. 
2004). 
4.2.8 Statistical analysis 
In study I, continuous variables were described as means and standard deviations. 
The Moorehead-Ardelt scores were analyzed using a repeated measurements 
analysis of variance and the Tukey-Kramer method was used to adjust the p-values 
of pairwise comparisons of time points. The difference between the patients and the 
population sample in the mean 15D dimension level values and scores were tested 
using a two-tailed independent samples t-test. The few missing items of data on any 
dimension of the 15D questionnaire were replaced by predictions from regression 
models with the other dimensions and age as explanatory variables. A p<0.05 was 
considered statistically significant. 
In studies II-IV, sample size calculations were performed for %EWL using an 
equivalence design. Calculations were based on a test of mean difference between 
LRYGB and LSG, assuming the mean of 60 and standard deviation of 20 in the 
LRYGB group. An α level of .05 and power of 90% were used in calculations. The 
prespecified equivalence margins for the clinical significance of weight loss 
differences between LRYGB and LSG were −9 to +9 percent units of mean %EWL 
(DeMaria et al. 2002, Higa et al. 2001, Himpens et al. 2006); the aim was to evaluate 
the margins based on minimal clinically important difference. Based on these 
calculations, 108 patients per group were needed, and assuming 10% dropout rate, a 
total of 240 study patients were planned to be enrolled in the study. 
In studies II and III, means, ranges, and standard deviations were used for 
normally distributed continuous variables and medians and ranges for non-normally 
distributed continuous variables. Categorical variables were characterized using 
frequencies and percentages. Associations between categorical variables were 
statistically tested using Pearson’s χ2 test, and for small frequencies, Fisher’s exact 
test was used. Differences between groups in normally distributed continuous 
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variables were tested using independent samples t-test, and for non-normally 
distributed variables, the Mann–Whitney U-test was used. The p-values < 0.05 were 
considered statistically significant. Statistical analyses were performed using SAS 
System for Windows ver. 9.2 (SAS Institute, Cary, NC, USA). 
In study IV, means and standard deviations were used for continuous variables 
except for micronutrient concentrations, for which medians and ranges were used. 
Categorical variables were characterized using frequencies and percentages. 
 In study IV, equivalence of %EWL between the operations at different time 
points was evaluated using repeated-measurements analysis of variance (ANOVA). 
The model included operation, time passed from the operation, center, and diabetes 
status as independent variables, excess weight at the beginning of the study as a 
covariate, and interaction of operation and time. At every time point, 95% confidence 
intervals (CI) for the difference between the study groups were calculated, and 
equivalence was evaluated using the predefined margins of equivalence (−9 to 9). If 
the 95% CI of difference is within equivalence margins, the groups are equivalent.  
Repeated-measurements ANOVA was used to analyze the dependent variables, 
i.e. fasting plasma glucose levels and HbA1c values for patients with T2DM and 
levels of total cholesterol, LDL, HDL, and TG for all patients. All of the models 
included operation, time, and center as independent variables and also included 
interaction of operation and time. In the analyses of fasting plasma glucose and 
HbA1c values, preoperative use of insulin was also included in the model as an 
independent variable. In the analyses of lipid values, diabetes status was also 
included in the model as an independent variable. Repeated-measurements ANOVA 
tests for general differences across time points and, with the test of interaction of 
operation and time, tests whether the difference between the operations have any 
differences between the time points. According to the idea of repeated-measurements 
ANOVA, the difference between the study groups was evaluated separately at four 
points (0.5, 1, 3, and 5 years) only when the interaction of operation and time was 
statistically significant. If the interaction was not statistically significant, the results 
are presented by main-effects operation and time, meaning that mean estimates for 
operations are calculated across time points and mean estimates for time points are 
calculated for the whole dataset, not separately for operations. The QOL score was 
also analyzed using repeated-measurements ANOVA but including only baseline 
and 5 years in the analysis.  
Normality of the residuals of the models was evaluated visually and using the 
Kolmogorov-Smirnov test. For skewed variables (HbA1C, fasting glucose, HDL, 
and TG), logarithmic transformation was used to achieve normality. The results were 
quantified using least squares mean (95% CI) estimates and difference (95% CI) 
between operations. When logarithmic transformation was used for analyses, 
estimates were transformed to the original scale, but for those variables differences 
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are not presented, because back-transformed estimates for difference represent the 
ratio of group means, not the difference. For categorical variables, differences 
between study groups were evaluated using Pearson χ2 or Fisher exact test. Post hoc 
analyses included BMI for the whole study group and %EWL and BMI in patients 
with diabetes. All post hoc analyses were performed using repeated-measurements 
ANOVA as described above. Differences between groups at the five-year point 
regarding vitamin deficiencies in the whole study group were evaluated using the 
Mann-Whitney U-test.  
P-values for multiple comparisons were adjusted using the step-down Bonferroni 
method of Holm. Analyses were performed according to the intention-to-treat 
population, i.e. all patients were analyzed in their original intervention group, and 
missing data were excluded from the analyses. Because of missing values at least at 
one time point (60/240 patients (25%)), a sensitivity analysis using multiple 
imputation was performed for the primary outcome (%EWL). Multivariate 
imputation by fully conditional specification method was performed. The predictive 
mean matching method was used to construct ten imputed datasets, and repeated-
measurements ANOVA was performed for each. The results of these sensitivity 
analyses were compared with the original analysis of %EWL.  
Two-sided p-values < 0.05 were considered statistically significant. Statistical 
analyses were performed using SAS version 9.4 (SAS Institute Inc), and all figures 
were drawn with R version 3.2.0 (R Foundation for Statistical Computing). 
4.2.9 Ethics 
Study I was approved by the Ethics Committee of Vaasa Healthcare District. 
SLEEVEPASS trial (studies II-IV) was approved by the Ethics Committee of Turku 
University Hospital and all participating hospitals. The patients were thoroughly 
informed of both of the operative techniques at the preoperative outpatient clinic 
visits. However, at the time of enrollment, there was no long-term data on LSG 
available. A written informed consent was obtained from all patients at the outpatient 
clinic by the study group surgeon. SLEEVEPASS trial was registered at 
clinicaltrials.gov (NCT00793143). 
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5 Results 
5.1 QOL after LAGB for morbid obesity (I) 
Preoperatively, the mean age of the 101 patients was 43 years (range 23-66, SD 10.7) 
and 75% were female. The mean preoperative BMI was 46.3 kg/m² (range 36.3-66.6, 
SD 6.3). Of the 101 patients enrolled in this study, 71 (70%) suffered from at least 
one of the common comorbidities associated with morbid obesity, such as T2DM, 
hypertension, OSA or arthrosis. Four procedures (4%) had to be converted from 
laparoscopy to open operation. During the five-year follow-up, seven patients (7%) 
went through revision laparoscopy because of band leakage and a total of 13 patients 
(13%) had to have their band removed. The mean %EWL was 37.3% (SD 16.5) at 
one-year follow-up and 57.9% (SD 31.1) at five years. 
The preoperative DSQOL scores were significantly improved on all five 
domains of the Moorehead-Ardelt questionnaire at one-year follow-up but no 
significant further change was seen after that until the five-year follow up (Table 2).  
Table 2.  Moorehead-Ardelt quality of life scores preoperatively, and at 1, and 5 years after 
laparoscopic adjustable gastric banding (LAGB). Reproduced with the permission of 
the copyright holders. 
 
 
Dimensions 
 
 
Score range 
Preoperative 
group 
(n=95) 
1-year 
postoperative 
group (n=73) 
5-year 
postoperative 
group (n=63) 
 
 
P-values* 
Self-esteem -1 to +1 -0.01 (0.39) 0.44 (0.37) 0.40 (0.43) <0.01, <0.01, 0.43 
Physical -0.5 to +0.5 0.14 (0.23) 0.29 (0.19) 0.30 (0.19) <0.01, <0.01, 0.96 
Social -0.5 to +0.5 -0.23 (0.23) 0.07 (0.23) 0.13 (0.25) <0.01, <0.01, 0.22 
Labor -0.5 to +0.5 -0.04 (0.26) 0.15 (0.25) 0.19 (0.25) <0.01, <0.01, 1.00 
Sexual -0.5 to +0.5 -0.03 (0.30) 0.09 (0.24) 0.08 (0.33) 0.04, 0.05, 0.87 
Total score -3 to +3 -0.17 (1.08) 1.04 (0.90) 1.10 (1.16) <0.01, <0.01, 0.94 
Values are means (standard deviation), 95% confidence intervals. *P-values derived from the 
differences between the preoperative group and the 1-year postoperative group, between the 
preoperative group and the 5-year postoperative group, and between the two postoperative groups, 
in that order. 
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Of the 15 different dimensions recorded in the 15D HRQOL questionnaire, a 
significant improvement was seen in the dimensions of moving, breathing, sleeping, 
usual activities, depression, distress, vitality and sexual activity at one-year follow-
up compared to preoperative values. A significant worsening was seen in the 
dimension of eating at one year. The improvements at one-year follow-up also 
remained at five years except for the dimensions of sleeping and distress. The one-
year worsening of eating was no longer evident at five-year follow-up. At one year 
after surgery, HRQOL had improved in a statistically significant manner as indicated 
by the mean total 15D score (0.836 vs. 0.900 for preoperative vs. one-year follow-
up, respectively, p < 0.001). This improvement was maintained until five years after 
surgery (mean total 15D score 0.899, preoperative vs. five-year follow-up p < 0.001), 
and there was no difference in the total 15D scores between the one-year and five-
year assessments (p = 0.262). Despite these improvements, HRQOL of the bariatric 
patients remained at a lower level when compared with the age- and gender-
standardized general population (Figure 8). 
 
Figure 8.  15D quality of life score profiles of patients before, and at 1, and 5 years after 
laparoscopic adjustable gastric banding (LAGB) compared with the age- and gender-
standardized general population. Reproduced with the permission of the copyright 
holders.  
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5.2 Comparison of outcomes of LSG and LRYGB 
in the treatment of morbid obesity: the 
SLEEVEPASS randomized clinical trial 
(studies II-IV) 
Among the 240 patients randomized in the SLEEVEPASS trial, 69.6% were women, 
the mean age was 48 years (range 23-67, SD 9), and the mean baseline BMI was 
45.9 kg/m² (range 35-66, SD 6.0). Baseline characteristics are presented in Table 3. 
There were no differences in demographic characteristics between the two study 
groups regarding sex, age, BMI, and obesity-related comorbidities.  
Table 3.  Baseline characteristics of the patients in the SLEEVEPASS trial. Reproduced with 
the permission of the copyright holders. 
Characteristics LSG (n= 121) LRYGB (n= 119) 
Age, mean (SD), years 48.5 (9.6) 48.4 (9.3) 
Sex, No. (%)   
Women 87 (71.9) 80 (67.2) 
Men 34 (28.1) 39 (32.8) 
Weight, mean (SD), kg 130.1 (21.5) 134.9 (22.5) 
BMI, mean (SD), kg/m² 45.5 (6.2) 46.4 (5.9) 
Type 2 diabetes, No. (%) 52 (43.0) 49 (41.2) 
Hypertension, No. (%) 83 (68.6) 87 (73.1) 
Dyslipidemia, No. (%) 39 (32.2) 45 (37.8) 
Moorehead-Ardelt QOL total score, mean (SD)* 0.10 (0.94) 0.12 (1.12) 
Hospitals participating in the study, No.   
Turku 40 40 
Vaasa 40 40 
Helsinki 41 39 
Abbreviations: LSG = Laparoscopic sleeve gastrectomy, LRYGB = Laparoscopic Roux-en-Y gastric 
bypass, BMI = Body mass index, QOL = Quality of life. * Score range -3 to +3, with higher score 
indicating better QOL 
Two patients in the LRYGB group were excluded from the study after the 
randomization, resulting in a total of 238 patients operated. In addition, one patient 
in the LRYGB group was converted to LSG during the operation due to technical 
difficulties, but was analyzed in the original randomized group according to 
intention-to-treat analysis. Of the 240 patients originally randomized, 193 (80.4%) 
completed the five-year follow-up. The flow of the participants through the trial is 
shown in Figure 9. 
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Figure 9.  Flow of participants through the SLEEVEPASS trial. Reproduced with the permission of 
the copyright holders. 
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5.2.1 The early 30-day results of the SLEEVEPASS study 
(II) 
The median operating time in the LSG group of 66 min (range 40-188) was 
significantly shorter than that in the LRYGB group of 94 min (range 52-195) (p < 
0.001). The median length of hospital stay was four days in both study groups (LSG, 
range 1-22 days; LRYGB, range 3-16 days). The overall 30-day morbidity was 
13.2% in the LSG group and 26.5% in the LRYGB group (p = 0.010). The rate of 
minor complications was lower after LSG (7.4%) compared to LRYGB (17.1%) (p 
= 0.023). The difference between the major complication rates was not statistically 
significant (LSG 5.8%, LRYGB 9.4%, p = 0.292). All the major and minor 30-day 
complications are presented in detail in Table 4. 
Table 4.  Early (<30-day) complications after laparoscopic sleeve gastrectomy and 
laparoscopic Roux-en-Y gastric bypass. Reproduced with the permission of the 
copyright holders. 
 
Complication category and type 
LSG 
 (n=121) 
LRYGB 
(n=117) 
 
P value 
Minor complications, No (%)    
Bleeding 3 (2.5) 2 (1.7)  
Intra-abdominal infection/infection of unknown origin 2 (1.7) 8 (6.8)  
Pneumonia 1 (0.8) 6 (5.1)  
Superficial wound infection 2 (1.7) 3 (2.6)  
Trocar site pain 1 (0.8)   
Dehydration  1 (0.9)  
Total 9 (7.4) 20 (17.1) 0.02 
Major complications, No (%)    
Bleeding 3 (2.5) 7 (6.0)  
Intra-abdominal infection/infection of unknown origin 1 (0.8) 3 (2.6)  
Pneumonia 1 (0.8)   
Bowel perforation 1 (0.8)   
Torsion of enteroanastomosis  1 (0.9)  
Outlet obstruction 1 (0.8)   
Total 7 (5.8) 11 (9.4) 0.29 
Overall morbidity 16 (13.2) 31 (26.5) 0.01 
Abbreviations: LSG = Laparoscopic sleeve gastrectomy; LRYGB = Laparoscopic Roux-en-Y gastric 
bypass 
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5.2.2 Weight-loss and remission of comorbidities at six-
month follow-up of the SLEEVEPASS study (III) 
The mean %EWL at six-month follow-up was 49.2% (range 10.7-94.8, SD 17.3) 
after LSG and 52.9% (range 18.2-85.9, SD 15.2) after LRYGB with no statistical 
difference between the study groups (p = 0.086). No differences were found 
regarding resolution of obesity related comorbidities at six months. T2DM was 
resolved or improved in 84.3% of patients after LSG and 93.3% after LRYGB (p = 
0.585). The corresponding results for hypertension were 76.8% and 81.9% (p = 
0.707) and for dyslipidemia 64.1% and 69.0% (p = 0.485).  
5.2.3 Five-year follow-up of the SLEEVEPASS study (IV) 
Weight loss 
At five years, the estimated mean %EWL was 49% (95% CI, 45-52) after LSG and 
57% (95% CI, 53-61) after LRYGB. The model-based estimate of mean %EWL was 
8.2 percentage units (95% CI, 3.2-13.2) higher in the LRYGB group than in the LSG 
group at five-year follow-up, as presented in Table 5. The groups were, thus, not 
equivalent based on the predefined margins of equivalence of -9 to 9. The difference 
in mean %EWL between LSG and LRYGB groups did not meet the criteria of 
equivalence at any of the registered time points of six months and one, three and five 
years. LRYGB resulted in statistically greater weight loss than LSG at five years, 
but the difference was not clinically significant.  
Across the follow-up, the change in BMI was significantly different between 
LSG and LRYGB groups (p < 0.001 for operation x time interaction). At five years, 
the mean estimate of BMI was 1.1 (95% CI, -0.5 to 2.6) units lower following 
LRYGB, but there was no statistically significant difference between the operations 
(p = 0.54). Regarding patients with T2DM, there was also no difference in the mean 
estimate of BMI (p = 0.29), which was 2.1 (95% CI, -0.2 to 4.5) units lower after 
LRYGB compared with LSG. For patients with T2DM, the study groups were not 
equivalent regarding %EWL at any of the time points. At five-year follow-up, the 
estimate of mean %EWL was 11.7% (95% CI, 3.7-19.7) lower in patients after LSG 
than LRYGB. These results are shown in Table 5, and Figures 10, and 11.  
 Table 5.  Excess weight loss mean differences and body mass index model-based means for the whole study group and for patients with diabetes 
after laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass at baseline and at 5 years. Reproduced with the 
permission of the copyright holders.  
 
 
Baseline 5y
EWL (%), mean difference between LRYGB and LSG (95% CI)*† 
All patients 8.2 (3.2 to 13.2)
Patients with diabetes 11.7 (3.7 to 19.7)
BMI (kg/m²), model based mean (95% CI)°†  [n]
All patients Operation *time: p<0.001
    LSG 47.3 (46.2 to 48.3) [121] 36.5 (35.4 to 37.6) [98]
    LRYGB 48.4 (47.3 to 49.5) [119] 35.4 (34.3 to 36.5) [95]
    Difference -1.1 (-2.6 to 0.40) 1.1 (-0.5 to 2.6)
    P-value 0.179
Patients with diabetes Operation *time: p<0.001
    LSG 46.3 (44.7 to 47.9) [52] 36.6 (35.0 to 38.3) [41]
    LRYGB 47.4 (45.8 to 49.0) [49] 34.5 (32.8 to 36.1) [41]
    Difference -1.1 (-3.4 to 1.1) 2.1 (-0.2 to 4.5)
    P-value 0.072
EWL = excess weight loss = (initial weight – follow-up weight) : (initial weight – ideal weight for BMI 25kg/m²) 
LSG = laparoscopic sleeve gastrectomy, LRYGB = laparoscopic Roux-en-Y gastric bypass, BMI = body mass index
* In EWL equivalence design was used in the analyses and equivalence margins were set from -9 to +9
° In BMI superiority design was used in the analysis
† Repeated measurements ANOVA
All the results are adjusted for center and diabetes status.
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Figure 10. Percent excess weight loss (%EWL) for the whole study group after laparoscopic sleeve 
gastrectomy and laparoscopic Roux-en-Y gastric bypass over the 5-year follow-up. 
%EWL at baseline represents preoperative weight loss between day of randomization 
and day of surgery. Lower and upper borders of boxes indicate 25th and 75th quartiles, 
respectively; lower and upper ends of error bars indicate minimum and maximum 
values, respectively; horizontal lines in boxes indicate median values; dots indicate 
mean values. Reproduced with the permission of the copyright holders. 
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Figure 11. Percent excess weight loss (%EWL) for patients with diabetes after laparoscopic sleeve 
gastrectomy and laparoscopic Roux-en-Y gastric bypass over the 5-year follow-up. 
%EWL at baseline represents preoperative weight loss between day of randomization 
and day of surgery. Lower and upper borders of boxes indicate 25th and 75th quartiles, 
respectively; lower and upper ends of error bars indicate minimum and maximum 
values, respectively; horizontal lines in boxes indicate median values; dots indicate 
mean values. Reproduced with the permission of the copyright holders. 
Remission of T2DM 
At five years postoperatively, the difference in T2DM remission was not significant 
between the study groups (p > 0.99). There was complete remission in 5/41 patients 
(12%) in the LSG group and 10/40 (25%) in the LRYGB group. Improved glycemic 
control was seen in both study groups at five years compared with baseline. The 
mean estimated fasting plasma glucose level was 7.5 (95% CI, 6.9-8.2) mmol/l in 
the LSG group and 6.7 (95% CI, 6.1-7.3) mmol/l in the LRYGB group with no 
statistically significant difference (p = 0.052). There was no difference between the 
study groups regarding HbA1C, the mean estimated value during the follow-up time 
of five years was 6.6% (95% CI, 6.4-6.8) in the LSG group and 6.6% (95% CI, 6.4-
6.8) in the LRGB group (p = 0.93).  
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Remission of other comorbidities 
At five-year follow-up, 14/30 patients (47%) in the LSG group and 24/40 (60%) in 
the LRYGB group had discontinued their dyslipidemia medications; 6/30 patients 
(20%) in the LSG group and 2/40 (5%) in the LRYGB group needed less 
medications; and no change was seen in 10/30 patients (33%) in the LSG group and 
14/40 (35%) in the LRYGB group (p = 0.15). For the whole study group, there was 
no statistically significant difference (p = 0.053) in total cholesterol values at five 
years between the study groups: 4.9 (95% CI, 4.7-5.0) mmol/l for the LSG group 
and 4.6 (95% CI, 4.5-4.8) mmol/l for the LRYGB group. Also, there was no 
difference in the HDL values: 1.4 (95% CI, 1.3-1.4) mmol/l for the LSG group and 
1.4 (95% CI, 1.3-1.5) mmol/l for the LRYGB group (p = 0.79). LDL values were 
significantly lower (p = 0.02) in the LRYGB group at five-year follow-up compared 
with the LSG group: 2.5 (95% CI, 2.3-2.6) mmol/l and 2.7 (95% CI, 2.6-2.9) mmol/l, 
respectively. The mean estimates of TG values across time were 1.2 (95% CI, 1.2-
1.3) mmol/l for the LSG group and 1.2 (95% CI, 1.1-1.2) mmol/l for the LRYGB 
group with no statistically significant difference between the study groups (p = 0.18). 
Regarding the 38 patients who had discontinued their dyslipidemia medication, 22 
had true remission (LDL < 3.0 mmol/l and no dyslipidemia medications) at five years 
postoperatively. For the LSG group, true remission was reached by 6/30 patients 
(20%) and for the LRYGB group 16/40 patients (40%). 
At five years after the operation, 20/68 patients (29%) in the LSG group and 
37/73 (51%) in the LRYGB group had discontinued their hypertension medications; 
24/68 (35%) in the LSG group and 22/73 (30%) in the LRGB group needed less 
medications; and no change in the hypertension medications was detected in 24/68 
(35%) and 14/73 (19%) patients, respectively (p = 0.02).  
Quality of life 
At five-year follow-up, the Moorehead-Ardelt questionnaire was used for DSQOL 
analysis. Mean Moorehead-Ardelt QOL total scores were 0.85 (SD, 1.08) for the 
LSG group and 0.76 (SD, 1.01) for the LRYGB group. The change in QOL did not 
differ significantly between the study groups (p = 0.70 for operation x time 
interaction). The difference in QOL between the groups was not statistically 
significant (p = 0.85), but total QOL score increased statistically significantly by 0.7 
(95% CI, 0.6-0.9) units from baseline until the follow-up at five years (p < 0.001). 
Morbidity between 30 days and five years  
All the late complications between 30 days and five years postoperatively are 
presented in detail in Table 6. During this follow-up, the overall morbidity rate was 
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19% (n = 23) for LSG and 26% (n = 31) for LRYGB with no statistically significant 
difference (p = 0.19) between the study groups. There was no treatment-related 
mortality during the follow-up of five years. 
Table 6.  Complications between 30 days and 5 years after laparoscopic sleeve gastrectomy 
and laparoscopic Roux-en-Y gastric bypass. Reproduced with the permission of the 
copyright holders. 
Complication category and type LSG n=121 LRYGB n=119 P value 
Minor complications, No (%)    
Vomiting/dehydration  3 (2.5)  
Gastroesophageal reflux 11 (9.1)   
Ulcer/ Srticture at gastrojejunal anastomosis 2 (1.7)* 6 (5.0)  
Dumping  3 (2.5)  
Nonspecific abdominal pain  1 (0.8)  
Total 13 (10.7) 13 (10.9) 0.96 
Major complications, No (%)    
Gastroesophageal reflux 7 (5.8)   
Intestinal herniation  17 (14.3)  
Incisional hernia 3 (2.5) 1 (0.8)  
Total 10 (8.3) 18 (15.1) 0.10 
Overall morbidity 23 (19.0) 31 (26.0)  
Abbreviations: LSG = Laparoscopic sleeve gastrectomy; LRYGB = Laparoscopic Roux-en-Y gastric 
bypass. * LSG converted to LRYGB, analysis according to intention-to-treat. 
Nutritional deficiencies 
All the patients were routinely prescribed multivitamins and calcium/vitamin D 
supplementation. Other supplementations were prescribed at the postoperative 
control visits when needed. At five-year follow-up, micronutrient concentrations 
including vitamin D, vitamin B12, albumin and folate were analyzed regardless of 
possible vitamin supplementation. There were no statistically significant differences 
in any of the median micronutrient levels between LSG and LRYGB (p > 0.05). 
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6 Discussion 
6.1 QOL after LAGB for morbid obesity (study I) 
Several studies have shown that QOL improves significantly after surgical treatment 
of morbid obesity (Muller et al. 2008, Kolotkin et al. 2009, Karlsson et al. 2007, 
Hammoud et al. 2009, Folope et al. 2008, Dziurowicz-Kozlowska et al. 2005). The 
results of our study confirm these findings and show that both DSQOL and HRQOL 
improve significantly after one year from LAGB and that these improvements are 
maintained up to five years after surgery. However, despite this sustainable 
improvement, HRQOL after LAGB was inferior compared to the level of HRQOL 
of the age- and gender-standardized general population.  
6.2 Comparison of LSG and LRYGB in the 
treatment of morbid obesity (studies II-IV) 
In the SLEEVEPASS trial including 240 morbidly obese patients randomized to 
undergo either LSG or LRYGB, criteria for equivalence in terms of the primary 
endpoint of %EWL at five years were not met between the two procedures. LRYGB 
resulted in greater %EWL at five years than LSG, but the CI for the difference 
extended the predefined equivalence margins of -9 to +9 percent units, and therefore 
no conclusions about clinical superiority of weight loss after LRYGB could be 
drawn. Importantly, both LSG and LRYGB were associated with sustained weight 
loss at long term, with a mean %EWL of 49% and 57%, respectively. There were no 
statistically significant differences between LSG and LRYGB regarding the 
secondary outcomes remission of T2DM and dyslipidemia, improvement of QOL, 
and overall morbidity. However, LRYGB resulted in better remission of 
hypertension than LSG, defined by the use of antihypertensive medication. 
Obesity and the related comorbidities are chronic diseases mandating assessment 
of the effectiveness of different bariatric procedures at long-term follow-up 
(Puzziferri et al. 2014). In this study, the weight loss was higher after LRYGB even 
though the difference was not statistically significant at five-year follow-up. In three 
relatively recent meta-analyses, a greater weight loss was found to result after 
LRYGB compared to LSG (Shoar and Saber 2017, Li et al. 2016, Chang et al. 2014). 
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However, these meta-analyses included mainly nonrandomized studies without 
appropriate controls. Similar findings of somewhat superior weight loss after 
LRYGB were reported in most of the RCTs, but these trials are limited either by the 
small number of enrolled patients (Ignat et al. 2017, Karamanakos et al. 2008, 
Kehagias et al. 2011, Zhang et al. 2014) or by different primary outcome (Schauer 
et al. 2017b) compromising assessment of differences between LRYGB and LSG. 
On the other hand, in the Swiss Multicenter Bypass or Sleeve Study (SM-BOSS), 
where the study protocol was quite similar to the SLEEVEPASS trial, no significant 
difference in %EBMIL between LSG and LRYGB was found at five years (Peterli 
et al. 2018).  
The variation in definitions for reporting weight loss outcomes after bariatric 
surgery must be taken into account. When this trial was designed in 2007, the 
standard of bariatric surgery outcome reporting was %EWL. Currently, new 
outcome reporting standards have been adopted and the preferred means of reporting 
weight loss after bariatric surgery include more than one weight loss outcome as they 
all have their benefits and limitations, i.e. it is recommended to report all of the 
different parameters including %EWL, %EBMIL, and %TWL. The outcome 
measure of %EWL is useful as a standard reporting parameter across populations, as 
it allows for comparison of individuals with varying initial weights and excess 
weights. The disadvantage of using %EWL is that it doesn’t reflect successful weight 
loss in very high BMI patients. This group of patients may end up with lower %EWL 
results despite achieving better absolute weight loss than lower BMI patients. Similar 
to %EWL, %EBMIL is dependent on initial weight measurements that can vary and 
be inconsistent. In different studies, initial weight can mean anything from 
measurements taken months before surgery to a measurement taken on the day of 
surgery with no established standard. The benefit of using %TWL is that it is easy 
to measure and comprehend by both physicians and patients. The limitation of using 
%TWL is that in the setting of variable clinically ideal and initial weights, the data 
can be clinically misleading. A heavier patient with more excess weight needs to lose 
more weight than a less heavy patient to reach a similar clinical impact and approach 
a normal weight range. (Brethauer et al. 2015)  
In general, bariatric surgery is shown to be superior to conservative medical 
therapy for treatment of T2DM (Schauer et al. 2017b, Courcoulas et al. 2015, 
Halperin et al. 2014, Ikramuddin et al. 2013). In other randomized trials, there are 
better T2DM remission rates associated with LRYGB than LSG, at least in the long 
term (Yu et al. 2015, Wang et al. 2015, Yang et al. 2015, Keidar et al. 2013, Osland 
et al. 2017). In this trial, no statistically significant differences in remission rates of 
T2DM could be shown between the two procedures up to five-year follow-up. 
However, the SLEEVEPASS trial was not powered to detect differences for T2DM 
remission. In a similar way, the SM-BOSS trial (Peterli et al. 2018) and the 
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STAMPEDE trial (Schauer et al. 2017b) both showed no significant differences in 
T2DM control between LSG and LRYGB, but they both were also underpowered 
for detecting differences regarding this outcome. The overall remission rate of 
T2DM was higher in the SM-BOSS trial than in this trial (Peterli et al. 2018). This 
could be attributable to possible differences in patient demographics and severity of 
the disease, such as preoperative T2DM duration. A longer duration of T2DM at 
baseline is associated with worse outcomes in remission rates after bariatric surgery 
(Sjöström et al. 2014, Dixon et al. 2013). 
In the SLEEVEPASS trial, LRYGB resulted in significantly higher rates of 
remission of hypertension than LSG at five years assessed by use of antihypertension 
medication. However, medication use is not an objective outcome for detecting 
hypertension as medication adherence may be suboptimal and it does not provide 
objective evidence of normotension (Lauffenburger et al. 2017). Similarly, based on 
medication use, there was no significant difference in the remission rates for 
dyslipidemia between the LSG and LRYGB groups. The measured LDL values were 
significantly lower at five years after LRYGB, while the total cholesterol, HDL, and 
TG values showed no differences between the study groups. These findings are 
consistent with observations in other studies, including the SM-BOSS trial (Peterli 
et al. 2018). 
QOL improved significantly after both LSG and LRYGB during the five-year 
follow-up compared with baseline, and there were no significant differences between 
the study groups. These findings are in accordance with previous literature (Rubino 
et al. 2016). 
6.3 Limitations of the studies 
The main limitation in study I was the missing data concerning possible 
improvement of obesity related comorbidities postoperatively and their potential 
association to changes in reported QOL. This was mainly due to insufficient 
recording of information at the postoperative follow-up visits, and the information 
could not be obtained retrospectively from the patient records. In addition, no 
analysis of changes in QOL in relation to weight loss was performed. The 
comparatively low number of patients with data on 15D QOL questionnaire can be 
considered a further limitation of this study. 
The randomized SLEEVEPASS trial (studies II-IV) also has several limitations. 
First, at the initiation of the study in 2008, only a small number of bariatric operations 
(n=430) were performed in the whole country that year. Since then, the number of 
annual operations in Finland has been growing but reached a plateau during the 
recent few years. There were no hospitals specialized in bariatric surgery and none 
of the study hospitals could be considered a high-volume center. However, despite 
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the limited experience from bariatric surgery at the initiation of this study, all of the 
operating surgeons participating in this study were experienced laparoscopic 
surgeons. This individual and institutional learning curve effect may have a role in 
the relatively high number of reoperation rates for both LSG and LRYGB when 
compared with other studies (Chang et al. 2014), but the effect does not bias the 
group comparison.  
An additional limitation of studies II-IV is the fact that information on patients 
not included in the SLEEVEPASS trial were not properly recorded. However, as the 
subjects participating in the study included most of the patients undergoing bariatric 
surgery at the study hospitals during the study enrollment period, the trial population 
can be considered representative of the average bariatric surgery population.  
A randomized clinical trial is always limited by the original statistical setting. In 
the SLEEVEPASS trial, we used the equivalence approach with predefined 
equivalence margins. However, at the time of study initiation, there was very little 
data on the long-term results after LSG. Based on this, the predefined equivalence 
margins had to be set somewhat arbitrarily, which may have an effect on the 
assessment of clinical importance of %EWL. 
A further limitation is the fact that this study is underpowered for detecting 
differences in remission rates of T2DM between LSG and LRYGB. Even though no 
significant differences between the study groups were found up to five-year follow-
up, no firm conclusions can be drawn from the present study. In addition, sufficient 
information regarding duration of T2DM at baseline was lacking at the 5-year 
follow-up, but has since then been retrieved retrospectively. This represents a 
limitation of the study, because T2DM duration has been shown to predict long-term 
postoperative remission (Brethauer et al. 2013, Jiménez et al. 2012).  
Obesity in itself is known to be a major risk factor for GERD symptoms, with an 
odds ratio of 1.73 (Eusebi et al. 2018). This increased risk of GERD is also a 
drawback of LSG (Arman et al. 2016, DuPree et al. 2014). It can be either 
exacerbation of prevalent disease at baseline or new onset (“de novo”) GERD. 
Severe reflux can make the patients depend permanently upon proton pump inhibitor 
(PPI) medication and worsen their QOL. In addition, reflux can lead to esophagitis 
and Barrett’s esophagus, which in turn represents a potential risk factor for the 
development of esophageal adenocarcinoma (Drahos et al. 2016). Depending on the 
length of the Barrett’s segment and the grade of dysplasia, the yearly incidence of 
development of Barrett adenocarcinoma varies from 0.3% to 2.4% (Anaparthy et al. 
2013). The potential progress from LSG induced GERD to actual malignancy in the 
distal esophagus takes undoubtedly several years to develop and can therefore only 
be identified by studies with longer follow-up and endoscopic surveillance. In recent 
studies, Barrett mucosa has been shown to develop in up to 17% of asymptomatic 
patients after LSG operation. However, most of these patients displayed non-
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dysplastic Barrett´s with only gastric (Type II) metaplasia and not intestinal (Type 
III) metaplasia (Felsenreich et al. 2017, Genco et al. 2017). However, there are still 
many discrepancies between different studies regarding the rates of development of 
Barrett’s esophagus after LSG as well as after bariatric surgery in general (Oor et al. 
2016).  
Insufficient assessment of prevalent GERD preoperatively is a major limitation 
of this study. Upper gastrointestinal endoscopy was performed on all patients before 
surgery, and severe GERD with large hiatal hernia was considered an exclusion 
criteria according to the study protocol. However, use of preoperative PPI 
medication was not properly recorded, there was no thorough standardized 
evaluation of the endoscopic findings, and no validated GERD symptom or DSQOL 
questionnaire was offered to the patients. In this study, 6% (n=7) of the patients in 
the LSG group underwent conversion from LSG to LRYGB for severe GERD, which 
was the most common reason for late reoperation in the LSG group. In addition, 9% 
(n=11) of the patients operated by LSG required daily PPI medication at five-year 
follow-up. A more standardized preoperative assessment of GERD might have 
resulted in better patient selection and avoiding the reoperations for GERD after 
LSG. However, at the time of the study initiation the concept of possible LSG 
associated GERD was not yet as clear as it is today. 
The fact that mesenteric defects were not routinely closed in the LRYGB 
operations at the time of this study represents also a limitation. In the LRYGB group, 
the most frequent reason for late reoperation was suspicion of internal hernia in 14% 
(n=17) of the patients. This complication rate was markedly higher than the rate of 
0.3-6% in other studies (Ortega et al. 2013, Dogan et al. 2015). The incidence of 
internal hernias following LRYGB would likely have been reduced by closure of the 
mesenteric defects at the primary operation (Stenberg et al. 2016, Stenberg et al. 
2017, Aghajani et al. 2017). This procedure is currently performed routinely, but it 
was not standard practice at the time of the set-up of the study. 
The rate of reoperations for major late complications was similar following LSG 
and LRYGB in this study, but the types of complications were different. Currently, 
at least some of these reoperations can be avoided by improved patient selection in 
LSG and by closure of the mesenteric defects in LRYGB. 
Approximately 20% of the patients randomized in the study were lost to follow-
up at five years, which might be considered a limitation. On the other hand, a follow-
up rate of 80% at 5 years is comparatively high and can therefore be considered a 
strength of the trial. Moreover, the drop-out rates were similar in LSG and LRYGB 
groups and multiple-imputation analysis suggested that there was little risk for bias 
based on the patients lost to follow-up. 
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6.4 Future perspectives 
LSG and LRYGB are the most commonly performed bariatric operations worldwide 
(Angrisani et al. 2018). They both result in good metabolic outcomes with high 
safety and good QOL (Nickel et al. 2017). However, these two procedures have 
different profiles regarding typical complications and causes for possible revisional 
surgery. One size does not fit all, and the optimal metabolic procedure is not the 
same for every patient. The aim in the future should be in tailoring a personalized 
prognostic algorithm to select the appropriate procedure for a given patient. Future 
research should concentrate on individual patient characteristics, such as BMI, 
comorbidities, other relevant conditions, and possibly genetic factors that could 
provide a composite endpoint score to guide optimal operation selection.  
Both LSG and LRYGB still need to be prospectively evaluated over an even 
longer period of time to further understand the long-term outcomes of these 
procedures. This is highlighted by the LSG induced GERD and Barrett’s esophagus, 
which require long-term follow-up with endoscopic surveillance. Health care 
professionals responsible for treating bariatric patients should make an effort to 
improve the patients’ adherence to follow-up and compliance with prescribed 
supplementations. It is also a reality that sometimes one bariatric operation is not 
sufficient for one patient in the course of several years. Revisional surgery may be 
needed for insufficient weight loss, weight regain, or complications from the original 
procedure. Obesity must be regarded a chronic disease that requires long-term 
follow-up also after bariatric surgery with readiness to treat upcoming issues 
according to best clinical practices.  
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7 Conclusions 
On the basis of the present investigations the following conclusions can be drawn: 
1) DSQOL and HRQOL improve significantly after LAGB. This QOL 
improvement is maintained at five-year follow-up although QOL does not 
reach the level of the general population. 
2) At 30-day postoperative analysis, LSG is associated with shorter operating 
time and fewer minor complications compared to LRYGB.  
3) At six months postoperatively, weight loss, resolution of comorbidities and 
complication rates do not differ between LSG and LRYGB. 
4) At five years postoperatively, LSG compared with LRYGB do not meet 
criteria for equivalence in terms of %EWL. Although LRYGB was associated 
with greater %EWL, the difference was not statistically significant, based on 
the prespecified equivalence margins. LRYGB resulted in higher rates of 
hypertension remission than LSG, but there were no differences in remission 
of T2DM and dyslipidemia, morbidity, mortality and improvement of QOL at 
five years. 
 
  58
Acknowledgements 
This study was carried out at the Department of Digestive Surgery, Turku University 
Hospital and in association with Department of Surgery, Vaasa Central Hospital and 
Department of Abdominal Surgery, Helsinki University Hospital. 
I would like to express my deep gratitude to my supervisor Professor Paulina 
Salminen for the endless support and inspiration during this long-lasting project. Her 
enthusiasm and visionary attitude toward combining top-level research and clinical 
surgical work serves as an example for us all. I would also like to thank my 
supervisor Docent Jari Ovaska for encouraging me to start this research project, 
introducing me to the field of bariatric surgery, and being supportive throughout the 
years.  
I gratefully acknowledge the reviewers Professor Anders Thorell and Docent 
Timo Heikkinen for their valuable comments to improve my manuscript. 
I wish to thank all my co-authors in the original publications for their important 
input in designing the studies, randomizing and operating the patients, collecting and 
interpreting the data, and revising the manuscripts. I am grateful to Professor Mikael 
Victorzon (deceased) and Professor Pirjo Nuutila for their valuable contributions. I 
would also like to thank Anne Juuti, Marja Leivonen, Pipsa Peromaa-Haavisto, 
Minna Soinio, Tero Vahlberg, Nabil Jaser, Pekka Tolonen, and Harri Sintonen for 
their efforts and contributions. I wish to express my extra thanks to Saija Hurme for 
her priceless support in biostatistics. 
 I would like to thank all the nurses at our outpatient clinic, who have been taking 
precious care of the study patients since the initiation of the SLEEVEPASS study.  
A special thanks goes to Niina Gröndahl, Anni Storrank, and Hanna Pernula. I also 
want to thank all the patients who participated in these studies. 
I would like to express my gratitude to Professor Juha Grönroos for creating a 
positive atmosphere for clinical research at our clinic. I would also like to thank my 
superiors Docent Arto Rantala and Docent Jukka Karvonen for encouragement to 
complete this project and for allowing me some time away from the clinical work to 
concentrate on research. 
I am grateful to all my colleagues and the nurses at the Department of Digestive 
Surgery in Turku University Hospital. It has been a pleasure to work with all of you 
Acknowledgements 
 59 
during the last several years. A special thanks goes to my long-time colleagues in 
upper GI surgery Risto Gullichsen, Simo Laine, Maija Lavonius, Saila Kauhanen, 
and Elina Lietzen. Despite the challenging clinical work, there has always been time 
for good humor and a relaxed atmosphere. Let’s keep up the good spirit! 
My deepest thanks go to all my family members for their endless love and 
support. I especially want to thank my Mom and Dad for having faith in me 
throughout my life. This project would never have been possible without your 
support. 
Finally, this thesis is dedicated to those who matter the most – my wife Päivi and 
our dear children Eero and Oiva. Thank you for enriching my life beyond measure. 
This work was financially supported by the Finnish government research funding 
(EVO), by Turku University Foundation, by the Finnish Medical Foundation, and by 
the Gastrointestinal Disorders Research Foundation. 
January 2020 
Mika Helmiö 
 
  60
Appendices 
Appendix 1. The 15D questionnaire. 
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Appendix 2. The Moorehead-Ardelt questionnaire. 
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